Medicamen Biotech Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh)
Medicamen Biotech Ltd · Outcome · 13 Nov 2026, 9:43 pm
Medicamen Biotech Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh) ■ Revenue: 5,483 (+16.2% YoY | +14.5% QoQ) ■ EBITDA: 869 (+68.5% YoY | +100.8% QoQ) ■ EBITDA Margin (%): 15.8 (+491 bps YoY | +681 bps QoQ) ■ PAT: 341 (+27.9% YoY | +61.0% QoQ) ■ EPS (INR): 3.04 (+94.9% YoY | +123.5% QoQ)
Original exchange filing (PDF)
More announcements from Medicamen Biotech Ltd
- Financial Results - Quarter and Half year ended on September 30, 2026 · 13 Nov 2026
- MEDICAMEN BIOTECH LIMITED has informed the Exchange about Board Meeting to be held on 13-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . · 13 Nov 2026
- MEDICAMEN BIOTECH LIMITED has informed the Exchange about Board Meeting to be held on 13-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . · 13 Nov 2026
- To consider and approve the financial results for the period ended September 30, 2026 · 13 Nov 2026
- Medicamen Biotech Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2026 ,inter alia, to consider and approve the unaudited financial .... · 13 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shivalik Rasayan Ltd & Growel Remedies Ltd · 26 Oct 2026
- Outcome of the meeting of Preferential Issue Commitee of the Board of Directors of Medicamen Biotech Limited to consider and approve the allotmentb of 5,00,000 Equity Shares pursuant to .... · 23 Oct 2026
- Trading Plan under SEBI (PIT) Regulations 2015 - Mr Sanjay Bansal · 30 Sept 2026
